Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Botox or Botox With Esophageal Dilation in Patients With Achalasia

NCT: NCT03654066 · ENROLLING_BY_INVITATION

NCT IDNCT03654066
StatusENROLLING_BY_INVITATION
Start Date2019-05-13
Completion2026-06

Brief Summary

Achalasia is a rare esophageal motility disorder. Treatment of achalasia is aimed toward palliation of symptoms. These include botox injections to the lower esophageal sphincter (LES), pneumatic dilation, surgical myotomy, and per-oral endoscopic myotomy (POEM). Botox injections are frequently used for patients that have significant comorbidities. The primary aim of this study is to assess symptomatic response of patient with achalasia to esophageal dilation and botox injection to the LES compared to standard therapy of only botox injection.

Frequently Asked Questions

What is Botox or Botox With Esophageal Dilation in Patients With Achalasia?

Botox or Botox With Esophageal Dilation in Patients With Achalasia is a clinical trial registered under NCT03654066. Current status: ENROLLING_BY_INVITATION.

What is the status of NCT03654066?

The current status of NCT03654066 (Botox or Botox With Esophageal Dilation in Patients With Achalasia) is: ENROLLING_BY_INVITATION.

When did Botox or Botox With Esophageal Dilation in Patients With Achalasia start?

Botox or Botox With Esophageal Dilation in Patients With Achalasia started on 2019-05-13.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.